drugset
drugset / Trial / NCT03000673

A Study to Evaluate Safety of Single Doses of BMS-986177 in Patients With End Stage Renal Disease (ESRD) Treated With Hemodialysis

NCT03000673 ↗

Phase 1/2 Completed 32 enrolled Bristol-Myers Squibb
RandomizedCrossoverOpen-labelTreatment

Summary

To investigate safety of Single Doses of BMS-986177 in Patients with End Stage Renal Disease treated with hemodialysis

Timeline

Start
2017-05-23
Primary completion
2017-10-23
Completion
2017-10-23

Drugs

EvaluationDrugModalityDoseRoute
Comparator Milvexian Small molecule — Oral
Comparator Enoxaparin sodium Other / unclassified — —
Comparator Heparin Other / unclassified — —

Indications

No indication recorded.